Clinical Outcomes of Hospitalized Patients with SARS-CoV-2 Omicron Variant vs. Influenza A During Influenza Season 2021 to 2022: A Retrospective Observational Study.


Journal

The Israel Medical Association journal : IMAJ
ISSN: 1565-1088
Titre abrégé: Isr Med Assoc J
Pays: Israel
ID NLM: 100930740

Informations de publication

Date de publication:
Sep 2023
Historique:
medline: 13 9 2023
pubmed: 12 9 2023
entrez: 12 9 2023
Statut: ppublish

Résumé

Influenza and coronavirus disease 2019 (COVID-19) are respiratory diseases with similar modes of transmission. In December 2021, influenza re-emerged after it had been undetected since March 2020 and the Omicron variant replaced the Delta variant. Data directly comparing the two diseases are scarce. To compare the outcomes of patients with both the Omicron variant and influenza during 2021-2022. We performed a retrospective study conducted in Beilinson hospital, Israel, from December 2021 to January 2022. We included all hospitalized patients with either laboratory-confirmed COVID-19 or influenza. The primary outcome was 30-day mortality. We identified 167 patients diagnosed with Omicron and 221 diagnosed with Influenza A. The median age was 71 years for Omicron and 65 years for influenza. Patients with Omicron had a significantly higher Charlson Comorbidity Index score (4 vs. 3, P < 0.001). Patients with Omicron developed more respiratory failure that needed mechanical ventilation (7% vs. 2%, P = 0.05) and vasopressors (14% vs. 2%, P < 0.001) than patients with influenza. In a multivariate model, 30-day mortality was lower in patients diagnosed with influenza than in patients diagnosed with Omicron (19/221 [9%] vs. 44/167 [26%], hazard ratio 0.45, 95% confidence interval 0.25-0.81). Patients diagnosed with Omicron had higher mortality than patients diagnosed with seasonal influenza. This finding could be due to differences in co-morbidities, the virus pathogenicity, and host responses to infection.

Sections du résumé

BACKGROUND BACKGROUND
Influenza and coronavirus disease 2019 (COVID-19) are respiratory diseases with similar modes of transmission. In December 2021, influenza re-emerged after it had been undetected since March 2020 and the Omicron variant replaced the Delta variant. Data directly comparing the two diseases are scarce.
OBJECTIVES OBJECTIVE
To compare the outcomes of patients with both the Omicron variant and influenza during 2021-2022.
METHODS METHODS
We performed a retrospective study conducted in Beilinson hospital, Israel, from December 2021 to January 2022. We included all hospitalized patients with either laboratory-confirmed COVID-19 or influenza. The primary outcome was 30-day mortality.
RESULTS RESULTS
We identified 167 patients diagnosed with Omicron and 221 diagnosed with Influenza A. The median age was 71 years for Omicron and 65 years for influenza. Patients with Omicron had a significantly higher Charlson Comorbidity Index score (4 vs. 3, P < 0.001). Patients with Omicron developed more respiratory failure that needed mechanical ventilation (7% vs. 2%, P = 0.05) and vasopressors (14% vs. 2%, P < 0.001) than patients with influenza. In a multivariate model, 30-day mortality was lower in patients diagnosed with influenza than in patients diagnosed with Omicron (19/221 [9%] vs. 44/167 [26%], hazard ratio 0.45, 95% confidence interval 0.25-0.81).
CONCLUSIONS CONCLUSIONS
Patients diagnosed with Omicron had higher mortality than patients diagnosed with seasonal influenza. This finding could be due to differences in co-morbidities, the virus pathogenicity, and host responses to infection.

Identifiants

pubmed: 37698307

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

585-589

Auteurs

Alaa Atamna (A)

Infectious Disease Unit, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Evgeny Berkov (E)

COVID-19 Inpatient Department, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.

Genady Drozdinsky (G)

Internal Medicine Department E, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Tzippy Shochat (T)

Statistics Division, Clinical Research Authority, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Haim Ben Zvi (H)

Clinical Microbiology Laboratory, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Noa Eliakim-Raz (N)

Internal Medicine Department E, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Jihad Bishara (J)

Infectious Disease Unit, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Avishay Elis (A)

Internal Medicine Department C, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel, Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH